Mantle Cell Lymphoma
Conference Coverage
'New benchmark' set in phase-3 blood cancer study
Phase 3 SHINE study of older patients with mantle cell lymphoma yields “profound” results with ibrutinib add-on.
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
Latest News
New trials in lymphoma and MM: Could your patient benefit?
Late-phase clinical trials are opening up, with a chance to enroll one or more of your patients.
Conference Coverage
ZUMA-2, TRANSCEND data pique interest in earlier CAR T for R/R MCL
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
From the Journals
New inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible inhibitor.
Management of refractory mantle cell lymphoma
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
Hepatitis screening now for all patients with cancer on therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical...
News
FDA okays new CAR T therapy, first for mantle cell lymphoma